Skip to content
Inciteful Med

Treatment Pathways: Starting Therapy and the GELF Criteria

Last updated:

Doctors use the GELF criteria to decide when follicular lymphoma requires treatment, checking for signs like large lymph nodes, organ issues, or low blood counts. Initial treatments usually involve immunotherapy like rituximab, often paired with chemotherapy or targeted drugs to achieve remission.

Key Takeaways

  • • The GELF criteria help doctors determine when follicular lymphoma has a high enough tumor burden to move from 'watch and wait' to active treatment.
  • • First-line treatments are highly effective and typically involve immunotherapy (rituximab), sometimes combined with chemotherapy or targeted drugs.
  • • Rituximab maintenance can extend your remission time, but it does not improve overall survival and may increase your risk of infections.
  • • Advanced treatments like CAR-T cell therapy and bispecific antibodies offer powerful options if the lymphoma returns after multiple prior therapies.

While many people with follicular lymphoma (FL) begin with a “watch and wait” approach, there often comes a time when the disease begins to cause physical problems or grows to a size that requires medical intervention. Deciding when to move from observation to active treatment is a carefully calculated process based on standardized medical “triggers” [1][2].

When to Start: The GELF Criteria

The most widely used tool for deciding when to start treatment is the GELF criteria (named after the French group that developed them). These criteria help doctors identify a high tumor burden—meaning the lymphoma is widespread or large enough that waiting could be risky [1][3].

You generally meet the criteria for starting treatment if you have at least one of the following [1][2]:

  • Large Tumor Mass: Any single lymph node or mass larger than 7 cm (about the size of a tennis ball).
  • Multiple Nodal Sites: Three or more separate lymph node groups that are each larger than 3 cm.
  • Organ Issues: The lymphoma is compressing an organ (like a kidney or the airway) or causing fluid buildup around the lungs (pleural effusion) or in the abdomen (ascites).
  • Symptomatic Spleen: Your spleen is so enlarged that it is causing pain or fullness.
  • Low Blood Counts (Cytopenia): The lymphoma in your bone marrow is preventing you from making enough healthy blood cells (e.g., hemoglobin below 10 g/dL or low platelets).
  • B-Symptoms: You are experiencing significant fevers, drenching night sweats, or unexplained weight loss.

First-Line Treatment Options

If you meet the GELF criteria, your doctor will discuss “induction” (initial) treatment options. These are highly effective and can involve combinations of immunotherapy and targeted drugs or chemotherapy [4].

  • Rituximab Monotherapy: For patients with very low tumor burden or those who are frail, immunotherapy alone can be highly effective without the toxicity of chemotherapy [4]. Rituximab is a monoclonal antibody that acts like a “homing beacon” for your immune system to destroy cancer cells [5].
  • Targeted Therapy (R-squared): A chemotherapy-free combination of rituximab and lenalidomide (an immune system modulator) is also a standard frontline option, particularly for those wishing to avoid chemotherapy [6].
  • Chemoimmunotherapy (Bendamustine, CHOP, or CVP):
    • BR (Bendamustine + Rituximab): Often the preferred choice because it is generally well-tolerated and highly effective [7].
    • R-CHOP: A more intensive combination of four chemotherapy drugs plus rituximab. It is often used if the doctor suspects the lymphoma is behaving more aggressively [8].

The Maintenance Debate

After completing 6 months of initial treatment, most patients achieve a remission. At this point, you and your doctor will discuss rituximab maintenance—receiving a dose of rituximab every 2 months for up to 2 years [4][9].

Factor Benefit/Risk
Progression-Free Survival (PFS) Maintenance significantly extends the time you stay in remission before the cancer returns [9][10].
Overall Survival (OS) Surprisingly, studies have not shown that maintenance helps patients live longer overall compared to waiting and treating the cancer when it relapses [9][11].
Immune System Health Maintenance can lead to long-term low levels of protective antibodies (hypogammaglobulinemia) and a higher risk of infections [12][7].
Lifestyle It requires 12 extra clinic visits over two years, which may affect your work or quality of life [13].

Advanced Options

If follicular lymphoma returns after two or more prior types of treatment, you may be a candidate for newer, highly effective therapies [14][15]:

  • Bispecific Antibodies: Drugs like mosunetuzumab act as a bridge, binding to both the cancer cell and your own healthy T-cells, bringing them together so your immune system can attack the lymphoma [16].
  • CAR-T Cell Therapy: This is a revolutionary ‘living drug’ where your own T-cells are collected, genetically re-engineered in a lab to recognize your cancer, and then infused back into your body to hunt down the lymphoma [14][17]. While currently a later-line option, it offers the potential for deep and very durable remissions [16][18].

Frequently Asked Questions

What are the GELF criteria for follicular lymphoma?
The GELF criteria are a set of medical guidelines doctors use to determine if your follicular lymphoma has a high tumor burden and requires active treatment. They check for factors like large lymph node masses, fluid buildup, low blood counts, or severe symptoms like drenching night sweats.
What is the first-line treatment for follicular lymphoma?
Initial treatment often involves immunotherapy like rituximab. Depending on your health and tumor burden, it may be given alone, paired with a targeted immune modulator like lenalidomide (R-squared), or combined with chemotherapy (such as Bendamustine or R-CHOP).
Should I get rituximab maintenance therapy?
Maintenance therapy involves receiving rituximab every two months for up to two years after your initial treatment. While it significantly extends the time you stay in remission, studies have not shown that it helps patients live longer overall, and it can increase the risk of infections.
What are the treatment options if follicular lymphoma comes back?
If the lymphoma returns after two or more prior treatments, you may be eligible for advanced therapies. Options include bispecific antibodies or CAR-T cell therapy, which engineers your own immune cells to recognize and attack the lymphoma cells.

Questions for Your Doctor

  • • Based on my scans and blood work, do I meet any of the GELF criteria for starting treatment?
  • • If we decide to start treatment, would you recommend BR (Bendamustine-Rituximab), R-CHOP, or a chemo-free option like R-squared, and why?
  • • What are the specific benefits of rituximab maintenance for someone in my situation? Does it improve how long I will live, or just how long I stay in remission?
  • • If I choose maintenance therapy, what is the plan for monitoring my immune system and preventing infections?
  • • If my lymphoma doesn't respond well to initial chemoimmunotherapy, at what point would we consider CAR-T cell therapy or bispecific antibodies?

Questions for You

  • • Which of the GELF criteria am I experiencing (e.g., large nodes, fatigue, or night sweats)?
  • • How important is it to me to stay in remission as long as possible versus avoiding the extra two years of maintenance therapy visits?
  • • Do I have a strong support system if I experience side effects like fatigue or increased infections during treatment?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.

    Barraclough A, Agrawal S, Talaulikar D, et al.

    Haematologica 2024; (109(10)):3338-3345 doi:10.3324/haematol.2023.284538.

    PMID: 38450504
  2. 2

    Initial Treatment of High Tumor Burden Follicular Lymphoma.

    Freeman CL, Sehn LH

    Hematology/oncology clinics of North America 2020; (34(4)):673-687 doi:10.1016/j.hoc.2020.02.004.

    PMID: 32586573
  3. 3

    Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.

    Luttwak E, Kumar A, Salles G

    Leukemia & lymphoma 2025; (66(5)):818-829 doi:10.1080/10428194.2024.2447371.

    PMID: 39756047
  4. 4

    [Treatment strategies for follicular lymphoma].

    Fukuhara N

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2023; (64(9)):1019-1025 doi:10.11406/rinketsu.64.1019.

    PMID: 37899178
  5. 5

    Follicular Lymphoma Presenting as a Primary Omental Mass: A Case Report and Pathological Analysis.

    Raman S, Amitkumar K, Radhakrishnan B, Kumaran S

    Cureus 2024; (16(11)):e73810 doi:10.7759/cureus.73810.

    PMID: 39691120
  6. 6

    Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study.

    Chan T, Champagne JN, Boudreault JS

    Cureus 2024; (16(8)):e66124 doi:10.7759/cureus.66124.

    PMID: 39229411
  7. 7

    [Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study].

    Teramoto M, Sone T, Takada K, et al.

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2020; (61(6)):598-604 doi:10.11406/rinketsu.61.598.

    PMID: 32624531
  8. 8

    Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.

    Watanabe T, Matsuno Y, Wakabayashi M, et al.

    Hematological oncology 2024; (42(3)):e3272 doi:10.1002/hon.3272.

    PMID: 38595316
  9. 9

    Where to start? Upfront therapy for follicular lymphoma in 2018.

    Leonard JP, Nastoupil LJ, Flowers CR

    Hematology. American Society of Hematology. Education Program 2018; (2018(1)):185-188 doi:10.1182/asheducation-2018.1.185.

    PMID: 30504308
  10. 10

    One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?

    Roschewski M, Hill BT

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2019; (39()):467-476 doi:10.1200/EDBK_239065.

    PMID: 31099693
  11. 11

    Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.

    Gibiansky E, Gibiansky L, Buchheit V, et al.

    British journal of clinical pharmacology 2019; (85(9)):1935-1945 doi:10.1111/bcp.13974.

    PMID: 31050355
  12. 12

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910
  13. 13

    Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.

    Okosun J, Montoto S

    Hematology/oncology clinics of North America 2020; (34(4)):701-714 doi:10.1016/j.hoc.2020.02.006.

    PMID: 32586575
  14. 14

    CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma.

    Mohty R, Kharfan-Dabaja MA

    Therapeutic advances in hematology 2022; (13()):20406207221142133 doi:10.1177/20406207221142133.

    PMID: 36544864
  15. 15

    Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.

    Dickinson M, Martinez-Lopez J, Jousseaume E, et al.

    Leukemia & lymphoma 2024; (65(3)):323-332 doi:10.1080/10428194.2023.2289854.

    PMID: 38179688
  16. 16

    Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.

    Fowler NH, Dickinson M, Dreyling M, et al.

    Nature medicine 2022; (28(2)):325-332 doi:10.1038/s41591-021-01622-0.

    PMID: 34921238
  17. 17

    Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.

    Cohen JA, Ghobadi A

    Expert review of anticancer therapy 2022; (22(9)):903-914 doi:10.1080/14737140.2022.2096009.

    PMID: 35786133
  18. 18

    The discovery and development of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma.

    Kungwankiattichai S, Maziarz RT

    Expert opinion on drug discovery 2025; (20(11)):1357-1368 doi:10.1080/17460441.2025.2567291.

    PMID: 41039722

This page provides educational information about follicular lymphoma treatment pathways and the GELF criteria. It is not a substitute for professional medical advice. Always consult your hematologist or oncologist for personalized treatment decisions.

Stay up to date

Get notified when new research about Follicular lymphoma is published.

No spam. Unsubscribe anytime.